SON-DP / Qurgen - LARVOL DELTA

SON-DP in Participants with Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Qurgen Inc.

New P1 trial • Gastric Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

A First-in-Human, Open-label, Phase Ia Dose Escalation Study of SON-DP in subjects with advanced/metastatic solid tumors that have relapsed or are refractory/intolerant to standard of care therapies (ANZCTR) - P1 | N=48 | Withdrawn | Sponsor: Qurgen Australia Pty Ltd | Recruiting ➔ Withdrawn

Metastases • Trial withdrawal • Tumor mutational burden • Oncology • Solid Tumor • POU5F1 • TMB

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Qurgen Inc. | Phase classification: P1a/1b ➔ P1

Phase classification • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

A First-in-Human, Open-label, Phase Ia Dose Escalation Study of SON-DP in subjects with advanced/metastatic solid tumors that have relapsed or are refractory/intolerant to standard of care therapies (ANZCTR) - P1 | N=48 | Recruiting | Sponsor: Qurgen Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Tumor mutational burden • Oncology • Solid Tumor • POU5F1 • TMB

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1a/1b | N=150 | Recruiting | Sponsor: Qurgen Inc.

Metastases • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor